Alcanza Clinical Research and Climb, a software provider, have inked a partnership focused on streamlining digital clinical trials for sites and patients.
As digital clinical trials become the norm in the CRO industry and patients begin to see participating in trials as a healthcare alternative, the two companies want to make the process easier and faster, according to a May 31 press release.
Financial terms of the agreement weren’t disclosed.
“Partnering with Climb will help deliver on a critical component of our commitment to inclusive research,” Carlos Orantes, Alcanza’s CEO, said in the release. “Recruitment and retention among traditionally underrepresented populations relies on patient-friendly experiences and convenience to lower the burden of clinical trial participation.”
Climb’s founder, Jay Holley, added that “the patient experience is more important than ever, as a flourishing pipeline of next-generation medicines depend on patient volunteers to advance therapies that can significantly improve and extend quality of life.”
Alcanza operates sites in Florida, Massachusetts, Michigan, New Hampshire, South Carolina and Virginia. The company specializes in psychiatry, neurology, dermatology and infectious disease therapeutic areas.
Climb, which was founded in 2019, offers a clinical study operations platform that allows patients to manage their progress throughout a trial.